The FDA approved a new therapy, Susvimo (ranibizumab injection) from Genentech, indicated for intravitreal use via ocular implant for wet age-related macular degeneration (AMD) with
A little over two years ago we reported on the approval of yet another biosimilar to Humira (yawn), Cyltezo (adalimumab-adbm) a sub-q therapy from Boehringer
Last week we published a review of the 2021 Medication Access Report which detailed a variety of access barriers including COVID-19, logistics, financial burdens, and
We’ve written frequently on two of the biggest trends in channel access, the shift away from buy-and-bill to other, less costly, sites of service as
We all know that the past year has been nothing short of a massive monkey wrench thrown into the US healthcare machinery and the impacts
The debate over rebate appropriateness has heated up over the past year. The focus on drug spend is now burning bright, especially given the current
Earlier this month the FDA approved a new Infused therapy, Tivdak (tisotumab vedotin-tftv) from Seagen Inc., for adult patients with recurrent or metastatic cervical cancer
Earlier this month the FDA approved a new ORAL specialty therapy, Exkivity (mobocertinib) from Takeda Pharmaceutical, for the treatment of adult patients with advanced or
Frequent readers of this report know that one of our favorite topics is health-system-owned specialty pharmacies. So, it was with great interest that we read
The FDA approved a new intravitreal injection this week, Byooviz (ranibizumab-nuna) from Samsung Bioepis, as the first ophthalmology biosimilar in the United States. It references
